A three-drug combination for aggressive advanced breast cancer doubles the length of time before the cancer progresses, compared with a drug combination currently available on the NHS, new research has shown.
Ellrott et al. provide a means to assign patient samples from clinical trials and other cancer genome studies to published TCGA molecular subtypes. Applying machine learning…
Take this survey powered by surveymonkey.com. Create your own surveys for free.
In the USA, before a patient can receive certain treatments or medications, a prior authorisation from their health insurance company is needed. A new USA-wide…
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
The Cellular Cancer Biology Imaging Research (CCBIR) Centers are developing and testing enabling imaging technologies at the cellular and organ scales driven by specific fundamental…
Overview for AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
Sameem Abedin, MD, Medical College of Wisconsin, Milwaukee, WI, discusses a Phase I study investigating CLAG-M salvage chemotherapy and lintuzumab-Ac225, a radio-labeled antibody against CD33,…
Therapeutic options for PD-1 refractory skin cancer 3 Jan – 6PM BST | 1PM EDT | 10AM PDT Allison Betof Warner, Omid Hamid, Inderjit Mehmi…
Neoadjuvant chemotherapy’s effect on local disease management of breast cancer has a number of clinical implications, including tumor downsizing, potentially improved overall survival, and more.
